Anthracycline antibiotics are among the most effective and commonly used anticancer drugs. Unfortunately, their clinical use is restricted by dose-dependent toxicity. Doxorubicin is an anthracycline antibiotic and cytotoxic (antineoplastic) agent. It is commonly used against ovarian, breast, lung, uterine and cervical cancers, Hodgkin's disease, soft tissue and primary bone sarcomas, as well against in several other cancer types. It has been shown that free radicals are involved in doxorubicin-induced toxicity. Doxorubicin causes the generation of free radicals and the induction of oxidative stress, associated with cellular injury. This review illustrates recent applications of different natural products, drugs, drug delivery systems, and approaches for protection against doxorubicin-induced toxicity (2006-present).
MinottiG.MennaP.SalvatorelliE.Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev56, 185–229 (2004).
5.
NgR.BetterN.GreenM. D.Anti-cancer agents and cardiotoxicity. Semin Oncol33, 2–14 (2006).
6.
FloydJ.MirzaI.SachsB.Hepatotoxicity of chemotherapy. Semin Oncol33, 50–67 (2006).
7.
MeadorsM.FloydJPerryM. C.Pulmonary toxicity of chemotherapy. Semin Oncol33, 98–105 (2006).
8.
StebbingJ.JonesA.Barrett-LeeP.Cardiotoxicity and anthracyclines. Breast Cancer Res Treat107, 451–453 (2008).
9.
FerrariM.Cancer nanotechnology: Opportunities and challenges. Nature5, 161–171 (2005).
10.
BanerjeeH. N.VermaM.Application of nanotechnology in cancer. Technol Cancer Res T7, 91–154 (2008).
11.
SinghK. K.Nanotechnology in cancer detection and treatment. Technol Cancer Res T4, 583 (2005).
12.
JainK. K.Targeted drug delivery for cancer. Technol Cancer Res T4, 311–313 (2005).
13.
QuilesJ. L.HuertasJ. R.BattionoM.Antioxidant nutrients and adriamycin toxicity. Toxicology180, 79–95 (2002).
14.
WolinskyJ. B.GrinstaffM. W.Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev60, 1037–1055 (2008).
15.
BrombergL.Polymeric micelles in oral chemotherapy. J Control Rel128, 99–112 (2008).
16.
BaguelyB. C.A brief history of cancer chemotherapy. In: Anticancer drug development, p. 1–11. Eds., BaguelyB. C.KerrD. J.El-sever Inc. Academic Press, London, UK (2001).
17.
HandeK. R.Topoisomerase II inhibitors. Update Cancer Ther3, 13–26 (2008).
PanjrathG. S.PatelV.ValdiviezoC. I.Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol49, 2457–2464 (2007).
20.
LuftF. C.Doxorubicin toxicity in the Iron Age. J Mol Med84, 529–531 (2006).
21.
MennaP.MinottiG.SalvatorelliE.In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biol Toxicol23, 49–62 (2007).
22.
MacannA.BredenfeldH.MullerR.-P.Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and belomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: A report by the German Hodgkin's lymphoma study group. Int J Radiat Oncol Biol Phys70, 161–165 (2008).
23.
MichinR. F.JohnstonM. R.SchullerH. M.Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer61, 1320–1325 (1988).
24.
de JongeM. J. A.VerweijJ.Renal toxicities of chemotherapy. Semin Oncol33, 68–73 (2006).
25.
XinY.-F.ZhouG.-L.DengZ.-Y.Protective effect of Lycium barbarum on doxorubicin-induced cardiotoxicity. Phytother Res21, 1020–1024 (2007).
26.
YouJ.-S.PanT.-L.LeeY.-S.Protective effects of Danshen (Salvia Miltiorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats. Phytother Res21, 1146–1152 (2007).
27.
MojzisovaG.MirossayL.KucerovaD.Protective effect of selected flavonoids on in vitro daunorubicin-induced cardiotoxicity. Phytother Res20, 110–114 (2006).
28.
RazaM.AlorainyM. S.AlghashamA. A.Evaluation of ambrein and epicoprostanol for their antioxidants properties: Protection against adriamycin-induced free radical toxicity. Food Chem Toxicol45, 1614–1619 (2007).
29.
HamzaA.AminA.DaoudS.The protective effect of a purified extract of Withania somnifera against doxorubicin-induced cardiac toxicity in rats. Cell Biol Toxicol24, 63–73 (2008).
30.
SantosR. V. T.JrM. L. B.CaperutoE. C.Chronic supplementation of cretine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats. Clin Exp Pharmacol Physiol34, 1294–1299 (2007).
31.
KaiserovaH.SimunekT.van der VijghW. J. F.Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta1772, 1065–1074 (2007).
32.
GokcimenA.CimA.TolaH. T.Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity. Human Exp Toxicol26, 519–525 (2007).
33.
GnanapragasamA.YogeetaS.SubhashiniR.Adriamycin induced myocardial failure in rats: Protective role ofCentella asiatica. Mol Cell Biochem294, 55–63 (2007).
34.
OzE.IlhanM. N.Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem286, 11–15 (2006).
35.
AndreadouI.SigalaF.IliodromitisE. K.Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol42, 549–558 (2007).
36.
YilmazS.AtessahinA.SahnaE.Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology218, 164–171 (2006).
37.
BastA.KaiserovaH.den HartogG. J. M.Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biol Toxicol23, 39–47 (2007).
38.
BastA.HaenenG. R. M. M.BruynzeelA. M. E.Protection by flavonoids against anthracycline cardiotoxicity: From chemistry to clinical trials. Cardiovasc Toxicol7, 154–159 (2007).
39.
QinX.-J.HeW.HaiC.-X.Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy. J Appl Toxicol28, 271–282 (2008).
40.
ChoiE. H.LeeN.KimH. J.Schisandra fructus extract ameliorates doxorubicin-induce cytotoxicity in cariomyocytes: Altered gene expression for detoxification enzymes. Genes Nutr2, 337–345 (2008).
41.
HanX.RenD.FanP.Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharmacol581, 47–53 (2008).
42.
JiangB.ZhangL.LiM.Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress. Food Chem Toxicol46, 1510–1515 (2008).
43.
ValadaresB. L. B.GrafU.SpanoM. A.Inhibitory effects of water extract of propolis on doxorubicin-induced somatic mutation and recombination in Drosophila melanogaster. Food Chem Toxicol46, 1103–1110 (2008).
44.
BenguedouarL.BoussenaneH. N.KebsaW.Efficiency of propolis extract mitochondrial stress induced by antineoplastic agents (doxorubicin and vinblastin) in rats. Ind J Exp Biol46, 112–119 (2008).
45.
ResendeF. A.de Andrade BarcalaC. A. M.da Silva FariaM. C.Antimutagenicity of ursolic acid and oleanolic acid against doxorubicin-induced clastogenesis in Balb/c mice. Life Sci79, 1268–1273 (2006).
46.
ChoiE. H.ChangH.-J.ChoJ. Y.Cytoprotective effect of anthocyanins against doxorubicin-induced toxicity in H9c2 cardiomyocytes in relation to their antioxidant activities. Food Chem Toxicol45, 1873–1881 (2007).
47.
KwiecienI.MichalaskaM.WlodekL.The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice. Eur J Pharmacol550, 39–46 (2006).
48.
LiL.LuQ.ShenY.Schisandrin B enchances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol71, 584–595 (2006).
49.
BeillerotA.DominguezJ.-C. R.KirschG.Synthesis and protective effects of coumarin derivatives against oxidative stress induced by doxorubicin. Bioorg Med Chem Lett18, 1102–1105 (2008).
50.
FerreiraA. L. A.YeumK. J.MatsubaraL. S.Doxorubicin as an antioxidant: Maintenance of myocardial levels of lycopene under doxorubicin treatment. Free Radic Biol Med43, 740–751 (2007).
51.
FerreiraA. L. A.SalvadoriD. M. F.NascimentoM. C. M. O.Tomato-oleoresin supplement prevents doxorubicin-induced cardiac myocyte oxidative DNA damge in rats. Mutat Res631, 26–35 (2007).
52.
LiuL.ShiR.ShiQ.Protective effect of saponins from Panax notoginseng against Dox-induced cardiotoxicity in mice. Planta Med74, 203–209 (2008).
53.
SinghG.SinghA. T.AbrahamA.Protective effects of Terminalia arjuna against doxorubicin-induced cardiotoxicity. J Ethnopharmacol117, 123–129 (2008).
54.
DasD. K.MaulikN.Resveratrol in cardioprotection: A therapeutic promise of alternative medicine. Molv Interv6, 36–47 (2006).
55.
ShuaiY.GuoJ.-B.PengS.-Q.Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosive impairment. Toxicol Lett170, 66–74 (2007).
56.
InjacR.PerseM.ObermajerN.Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials29, 3454–3460 (2008).
57.
InjacR.PerseM.BoskovicM.Cardioprotective effects of fullerenol C60(OH)24 on a single dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm. Technol Cancer Res T7, 15–26 (2008).
58.
InjacR.BoskovicM.PerseM.Acute doxorubicin nephrotoxicity in rats with malignant neoplasm is successfully treated with fullerenol C60(OH)24 through suppression of oxidative stress. Pharmacol Rep5, 742–749 (2008).
59.
InjacR.RadicN.GovedaricaB.Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress. Pharmacol Rep, In Press (2008).
60.
Djordjevic-MilicV.DjordjevicA.DobricS.Influence of fullerenol C60(OH)24 on doxorubicin induced cardiotoxicity in rats. Mater Sci Forum518, 525–529 (2006).
61.
JacevicV.Djordjevic-MilicV.Dragojevic-SimicV.Protective effects of fullerenol C60(OH)24 on doxorubicin-induced hepatotoxicity in rats: Patohistological study. Toxicol Lett172S, S146 (2007).
62.
YagmurcaM.BasO.MollaogluH.Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res38, 380–385 (2007).
63.
StolarskaM.MlynarskiW.Zalewska-SzewczykB.Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases — a clinical study including the pharmacoeconomic analysis. Pharmacol Rep58, 30–34 (2006).
64.
CzepasJ.Koceva-ChylaA.GwozdzinskiK.Different effectiveness of piperidine nitroxides against oxidative stress induced by doxorubicin and hydrogen peroxide. Cell Biol Toxicol24, 101–112 (2008).
65.
LiuL.-L.LiQ.-X.XiaL.Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology231, 81–90 (2007).
66.
HasinoffB. B.The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs17, 217–223 (2008).
67.
KimK.-H.OuditG. Y.BackxP. H.Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinosil 3-kinase-dependent pathway. J Pharmacol Exp Ther324, 160–169 (2008).
68.
Dragojevic-SimicV. M.JacevicV. M.BokonjicD. R.Protective effect of amifostine on doxorubicin-induced cardiac and renal toxicity in rats. Toxicol Lett164S, S257 (2006).
69.
PlandeJ.PlatelD.TariosseL.Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol Lett161, 37–42 (2006).
70.
dos SantosR. A.TakahashiC. S.Anticlastogenic and antigenotoxic effects of selenomethionine on doxorubicin-induced damage in vitro in human lymphocytes. Food Chem Toxicol46, 671–677 (2008).
71.
YehY.-C.LaiH.-C.TingC.-T.Protection by doxycycline against doxorubicin-induced oxidative stress and apoptosis in mouse testes. Biochem Pharm74, 969–980 (2007).
72.
KelishomiR. B.EjtemaeemehrS.TavangarS. M.Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology243, 96–104 (2008).
73.
GarciaJ. A. P.SimvoulidisL. F. N.SalluhJ. I. F.Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity. Int J Cardiol118, 406–407 (2007).
74.
FuP.ArcasoyM. O., Erytthropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Bichem Biophys Res Commun354, 372–378 (2007).
75.
CusakB. J.GamblielH.MusserB.Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Cehmother Pharmacol58, 517–526 (2006).
76.
WaldnerR.LaschanC.LohningerA.Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol132, 121–128 (2006).
77.
SakaguchiH.KodamaA.TomonariMPre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Breast Cancer Res Treat109, 443–450 (2008).
78.
de NigrisF.RienzoM.SchianoC.Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer44, 334–340 (2008).
79.
ChenX.ChenY.BiY.Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc Drugs Ther21, 367–374 (2007).
80.
ElblL.HrstkovaH.TomaskovaI.Late anthracycline cardiotoxicity protection by dexrayoxane (ICRF-187) in pediatric patients: Echocardiographic follow-up. Support Care Cancer14, 128–136 (2006).
81.
MukhopadhyayP.BatkaiS.RajeshM.Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol50, 528–536 (2007).
82.
IchiharaS.YamadaY.KawaiY.Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity. Biochem Biophys Res Commun359, 27–33 (2007).
83.
DjordjevicA.BogdanovicG.DobricS.Fullerenes in biomedicine. J BUON11, 391–404 (2006).
84.
InjacR.KocevarN.StrukeljB.Fullerenol C60(OH)24 as a potential drug. Farm Vest, In Press, (2008).
85.
TrajkovicS.DobricS.DjordjevicA.Radioprotective efficiency of fullerenol in irradiated mice. Mater Sci Forum494, 549–554 (2005).
86.
TrajkovicS.DobricS.JacevicV.Tissue-protective effects of fullerenol C60(OH)24 and amifostine. Coll Surf B58, 39–43 (2007).
ChiccoA. J.HydockD. S.CaroleM.Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol100, 519–527 (2006).
89.
MitraM. S.DonthamsettyS.WhiteB.Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol225, 90–101 (2007).
90.
DobsonJ.Magnetic nanoparticles for drug delivery. Drug Dev Res67, 55–60 (2006).
91.
KwonG. S.ForrestM. L.Amphiphilic block copolymer micelles for nanoscale drug delivery. Dev Res67, 15–22 (2006).
92.
PereverzevaE.TreschalinI.BodyaginD.Influence of the formulation on the tolerance of naoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. Int J Pharm337, 346–356 (2007).
93.
AzarmiS.TaoX.ChenH.Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm319, 155–161 (2006).
94.
DreisS.RothweilerF.MichaelisM.Preparation, characterisation and maintenance of drug efficay of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm341, 207–214 (2007).
95.
TewesF.MunnierE.AntoonB.Comparative study of doxorubicin-loaded poly(lactide-co-glycolide)nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm66, 488–492 (2007).
96.
WongH. L.RauthA. M.BendayanR.In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm65, 300–308 (2007).
97.
MissirlisD.KawamuraR.TirelliN.Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticle. Eur J Pharm Sci29, 120–129 (2006).
98.
XuX.ChenX.MaP.The release behavior of doxorubicin hydrochloride from medicated fibers prepared by emulsion-electrospinning. Eur J Pharm Biopharm (2008) doi:10.1016/j.ejpb.2008.03.010.
99.
MahmudA.XiongX.-B.LavasanifarA.Development of novel polymeric micellar drug conjugates and nano-containers with hydrolysable core structure for doxorubicin delivery. Eur J Pharm Biopharm (2008) doi:10.1016/j.ejpb.2008.02.021.
100.
JainK. K.Recent advances in nanooncology. Technol Cancer Res T7, 1–13 (2008).
101.
WuJ.LeeA.LuY.Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm337, 329–335 (2007).
102.
ChengW. W. K.AllenT. M.Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release126, 50–58 (2008).
103.
HanH. D.LeeA.HwangT.Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. J Control Release120, 161–168 (2007).
104.
CuiJ. X.LiC. L.GuoW. M.Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?J Control Release118, 204–215 (2007).
105.
HanH. D.LeeA.SongC. K.In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm313, 181–188 (2006).
106.
SadzukaY.SugiyamaI.TsurudaT.Characterization and cytotoxicity of mixed polyethylenglycol modified liposomes containing doxorubicin. Int J Pharm312, 83–89 (2006).
107.
HatakeyamaH.AkitaH.IshidaE.Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm342, 194–200 (2007).
108.
IshidaT.AtobeK.WangX. Y.Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effects of doxorubicin-encapsulation and high-dose first injection. J Control Release115, 251–258 (2006).
109.
HanH. D.ShinB. C.ChoiH. S.Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-acrylamide): Drug release behaviour and stability in the presence of serum. Eur J Pharm Biopharm62, 110–116 (2006).
110.
ElbayoumiT. A.TorchilinV. P.Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci32, 159–168 (2007).
111.
Di LorenzoG.Di TrolioR.MontesarchioV.Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma. Cancer112, 1147–1152 (2008).
112.
GilliesE. R.FrechetJ. M. J.Dendrimers and dendritic polymers in drug delivery. Drug Discov Today10, 35–43 (2005).
113.
LaiP.-S.LouP.-J.PengC.-L.Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release122, 39–46 (2007).
114.
StanczakA.FerraA.Prodrugs and soft drugs. Pharmcol Rep58, 599–613 (2006).
115.
HuF.-Q.WuX.-L.DuY.-Z.Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccgaride micelles encapsulating doxorubicin. Eur J Pharm Biopharm69, 117–125 (2008).
116.
HisseiniG. A.Abdel-JabbarN. M.MjalliF. S.Modeling and sensitivity analysis of acoustic release of doxorubicin from unstabilized pluronic P105 using an artificial neural network model. Technol Cancer Res T6, 1–56 (2007).
117.
LeeG. Y.ParkK.KimS. Y.MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm67, 646–654 (2007).
118.
TaoX.ChenH.SunX.-J.Formulation and citotoxicity of doxorubicin loaded in self-assembled bio-polyecectrolyte microshells. Int J Pharm336, 376–381 (2007).
119.
TianY.BrombergL.LinS. N.Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. J Control Release121, 137–145 (2007).
120.
DaiX.YueZ.EcclestonM. E.Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells. Nanomed4, 49–56 (2008).
121.
Di StefanoG.FiumeL.BaglioniM.Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin. Eur J Pharm Sci30, 136–142 (2007).
122.
ColomboP.-E.BousttaM.PoujolS.Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur J Pharm Sci31, 43–52 (2007).
123.
ChytilP.EtrychT.KonakC.Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: Effect of polymer chain modification. J Control Release115, 26–36 (2006).
124.
EtrychT.MrkvanT.RihovaB.Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. J Control Release122, 31–38 (2007).
125.
EtrychT.ChytilP.MrkvanT.Conjugated of doxorubicin with graft HPMA copolymers for passive tumor targeting. J Control Release (2008), doi:10.1016/j.jconrel.2008.04.017.
126.
KakinokiS.TaguchiT.SaitoH.Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: Characterization and in vitro evaluation. Eur J Pharm Biopharm66, 383–390 (2007).
127.
KakinokiS.TaguchiT.Antitumor effect of an injectable in-situ forming drug delivery system composed of a novel tissue adhesive containing doxorubicin hydrochloride. Eur J Pharm Biopharm67, 676–681 (2007).
128.
BidewellG. L.FoktI.PriebeW.Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol73, 620–631 (2007).
129.
LaatschH.FotsoS.Naturally occurring anthracyclines, in Anthracycline Chemistry and Biology I: Biological Occurrence and Biosynthesis, Synthesis and Chemistry, Vol. 1, pp. 3–74. Ed., KrohnK.. Springer, Berlin (2008).
130.
NiemiJ.Metsa-ketelaM.SchneiderG.Byosintetic anthracycline variants, In Anthracycline Chemistry and Biology I: Biological Occurrence and Biosynthesis, Synthesis and Chemistry, Vol. 1, pp 75–100. Ed., KrohnK.. Springer, Berlin (2008).
131.
Metsa-ketelaM.NiemiJ.MantsalaP.Anthracycline biosynthesis: Genes, enzymes and mechanisms, In Anthracycline Chemistry and Biology I: Biological Occurrence and Biosynthesis, Synthesis and Chemistry, Vol. 1, pp 101–142. Ed., KrohnK.. Springer, Berlin (2008).
132.
BerettaG. L.ZuninoF.Molecular mechanisms of anthracycline activity, in Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and new drugs, Vol. 2, pp. 1–20. Ed., KrohnK.. Springer, Berlin (2008).
133.
MennaP.SalvatorelliE.GianniL.Anthracycline cardiotoxicity, In Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and new drugs, Vol. 2, pp 21–44. Ed., KrohnK.. Springer, Berlin (2008).
134.
KratzF.Acid-sensitive prodrugs of doxorubicin, in Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and new drugs, Vol. 2, pp. 73–98. Ed., KrohnK.. Springer, Berlin (2008).
135.
FlorentJ.-C.MonneretC.Doxorubicin conjugates for selective delivery to tumors, in Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and new drugs, Vol. 2, pp. 99–140. Ed., KrohnK.. Springer, Berlin (2008).
136.
KochT. H.BarthelB. L.KaletB. T., Anthracycline-form-aldehyde conjugates and their targeted prodrugs, In Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and new drugs, Vol. 2, pp 141–170. Ed., KrohnK.. Springer, Berlin (2008).
